Aethlon Medical, Inc. — Form 10-Q Summary
Business context and reporting period. Aethlon is a clinical-stage medical therapeutics company developing the Hemopurifier for cancer and life-threatening infections. This quarterly report covers the three and nine months ended December 31, 2022, the company’s fiscal third quarter. The Hemopurifier has FDA Breakthrough Device designation for specified cancer and viral-disease indications; this designation is not FDA marketing approval.
Financial results and position
| Metric | Three months ended Dec. 31, 2022 | Nine months ended Dec. 31, 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | $0 | $0 | $17,117 and $281,049, respectively |
| Operating expenses | $2.85 million | $9.42 million | $2.55 million and $6.92 million |
| Operating loss | $2.85 million | $9.42 million | $2.53 million and $6.64 million |
| Net loss attributable to Aethlon | $2.85 million | $9.56 million | $2.53 million and $6.63 million |
| Loss per share, basic and diluted | $0.12 | $0.48 | $0.16 and $0.46 |
At December 31, 2022, cash was $17.50 million, working capital was $15.74 million, and total assets were $20.72 million. Total liabilities were $3.45 million, including $1.27 million of lease liabilities; the filing reports no conventional borrowings. The company used $7.56 million in operating cash and $0.93 million in investing cash during the nine months, while financing activities provided $8.92 million. Cash and restricted cash increased by $0.43 million to $17.59 million.
No meaningful profit margin is presented: the company reported no revenue in the current periods and continued to incur substantial operating expenses.
Material changes versus prior periods
- Nine-month operating expenses rose 36.2% to $9.42 million, while net loss increased to $9.56 million from $6.64 million. The expense increase included higher clinical-trial and manufacturing-related costs, professional fees, and payroll.
- Government contract revenue fell to zero from $281,049 for the nine-month comparison, as well as from $17,117 in the quarterly comparison. The University of Pittsburgh subaward was terminated after the site could not recruit patients; the company states completed work does not require repayment.
- Cash was slightly higher than at March 31, 2022, largely supported by equity issuance. Under its ATM program, Aethlon sold 7.48 million shares for net proceeds of $8.93 million, at an average price of $1.19 per share. Shares outstanding increased from 15.42 million at March 31 to 22.97 million at December 31.
- Property and equipment increased to $1.21 million from $0.44 million, primarily reflecting improvements and equipment for manufacturing and laboratory space.
Outlook, commentary, risks and unusual items
- Management stated that December 31 cash was expected to fund operations for at least 12 months from the February 13, 2023 filing date. It also expects continuing losses and negative cash flows and says additional capital will be needed for the foreseeable future.
- The company’s existing Hemopurifier inventory expired on September 30, 2022. Although 112 cartridges had passed quality-control measures, the company said they could not be shipped until FDA approval of its new GNA supplier; FDA review could take several additional months. This supply interruption may delay U.S. clinical trials.
- In oncology, the prior UPMC head-and-neck cancer study was terminated after only two patients were treated and further enrollment was not achieved. In January 2023, Aethlon engaged NAMSA to oversee oncology trials in the United States and Australia; it anticipated initial trials in Australia. The NCI contract closeout review may allow recognition of $574,245 in deferred revenue, but timing depends on the review.
- For COVID-19, one patient had completed participation in the Indian study, and two patients had been treated under U.S. single-patient emergency-use provisions. The filing does not report clinical efficacy conclusions.
- A non-cash $142,121 loss was recorded following approval to dissolve Exosome Sciences, Inc. Aethlon also disclosed a Nasdaq minimum-bid-price deficiency notice, with an initial deadline of April 24, 2023 to regain compliance; failure to do so could threaten continued listing.
- Other risks include reliance on limited or single-source suppliers, regulatory and clinical-trial uncertainty, potential dilution from future financing, and uncertain effects of inflation, the COVID-19 pandemic, and the war in Ukraine. The company reported no pending or threatened legal proceedings.
- Subsequent to quarter-end, Aethlon appointed Lee Arnold as part-time Chief Scientific Officer, effective February 1, 2023. Management reported disclosure controls and procedures were effective and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress and timing of FDA approval for the new GNA supplier, and whether the 112 cartridges can be released for use.
- Actual clinical-trial start dates, enrollment, costs, and results in Australia, the United States, and India.
- Timing and conditions for recognition of the $574,245 deferred NCI contract revenue after closeout review.
- Cash burn, financing needs, remaining ATM capacity, and dilution from further equity issuance.
- Nasdaq bid-price compliance status and any effect on the company’s listing or financing access.